Our Pricing

Wegovy Maintenance Dose After Goal Weight UK

Published on: June 03, 2026

Understanding your wegovy maintenance dose after goal weight uk options is crucial for sustaining long-term results. At Cured Pharmacy, our UK-registered clinical team provides personalised maintenance plans from £79.00, helping you transition from active weight loss to sustainable weight management with continued prescriber support.

What Happens When You Reach Your Goal Weight on Wegovy

Reaching your target weight on Wegovy (semaglutide 2.4mg) represents a significant achievement, but it marks the beginning of a new phase rather than the end of treatment. Clinical evidence from the STEP trials demonstrates that discontinuing semaglutide after achieving weight loss typically results in weight regain, with participants regaining approximately two-thirds of lost weight within one year of stopping treatment [1].

The STEP 4 trial specifically examined weight maintenance after achieving initial weight loss. Participants who continued semaglutide 2.4mg weekly maintained their weight loss and lost an additional average of 7.9% body weight over 48 weeks, whilst those switched to placebo regained 6.9% [1]. This evidence supports the approach of continuing Wegovy at an appropriate maintenance dose rather than stopping completely.

Your UK prescriber will assess multiple factors when determining your personalised maintenance strategy, including how much weight you've lost, how quickly you achieved your goal, your metabolic health markers, and any side effects experienced during the escalation phase. Maintenance doesn't necessarily mean staying at the maximum 2.4mg dose indefinitely.

Wegovy Maintenance Dose Options After Reaching Goal Weight

The standard maintenance approach involves continuing Wegovy at the dose that achieved your weight loss goal, typically 2.4mg weekly. However, some patients may maintain their results on lower doses, particularly if they experienced dose-dependent side effects during escalation [2].

Clinical practice in the UK has identified several maintenance strategies subject to prescriber approval. Some patients remain on the full 2.4mg dose, which provides maximum appetite suppression and metabolic benefit. Others may trial a step-down approach, reducing to 1.7mg weekly whilst monitoring weight stability over 8-12 weeks. A small proportion may find adequate maintenance at 1.0mg, though this lower dose typically provides less robust weight maintenance.

Your prescriber may recommend periodic dose adjustments based on your weight trajectory during maintenance. If you begin regaining weight on a reduced dose, returning to 2.4mg often restabilises weight without requiring the full escalation schedule again. Conversely, if you continue losing weight beyond your goal, a temporary dose reduction may be appropriate.

Personalising Your Maintenance Plan

Individual variation in semaglutide response means maintenance dosing cannot follow a one-size-fits-all protocol. Factors influencing your optimal maintenance dose include your baseline BMI, percentage of weight lost, concurrent lifestyle modifications, metabolic health improvements, and tolerability. Patients who have made substantial dietary and activity changes may maintain results on lower doses than those relying primarily on pharmacological appetite suppression.

Regular monitoring during the maintenance phase typically involves weight checks every 4-8 weeks initially, extending to every 12 weeks once stability is confirmed. Your UK prescriber will also monitor metabolic markers including HbA1c if you have type 2 diabetes, blood pressure, and lipid profiles to ensure continued metabolic benefit from ongoing treatment.

Long-Term Wegovy Use: Safety and Sustainability

Semaglutide has been studied for continuous use up to 104 weeks in obesity trials, with ongoing real-world data extending beyond two years [1][2]. The safety profile during long-term maintenance mirrors that seen during the weight loss phase, with gastrointestinal side effects typically diminishing over time as tolerance develops.

The most common side effects during maintenance include mild nausea, occasional diarrhoea, and constipation, though these are generally less frequent than during dose escalation. Serious adverse events remain rare, but ongoing monitoring for thyroid changes, pancreatitis symptoms, and gallbladder issues continues throughout treatment duration [3].

Long-term metabolic benefits extend beyond weight maintenance. Sustained semaglutide use has demonstrated continued improvements in cardiovascular risk markers, with the SELECT trial showing a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease [4]. These broader health benefits support the rationale for continued treatment even after achieving weight goals.

Combining Wegovy Maintenance with Lifestyle Modifications

Whilst Wegovy provides powerful pharmacological support for weight maintenance, integrating sustainable lifestyle changes optimises long-term outcomes and may allow for lower maintenance doses over time. The most successful maintenance strategies combine continued medication with established dietary patterns, regular physical activity, and behavioural modifications.

Nutritional approaches during maintenance should focus on nutrient-dense, whole foods that support satiety without excessive caloric density. Protein intake of 1.2-1.6g per kilogram of goal body weight helps preserve lean muscle mass, which is crucial for maintaining metabolic rate after significant weight loss. Regular resistance training two to three times weekly further protects against muscle loss and supports metabolic health.

Behavioural strategies proven to support weight maintenance include regular self-monitoring through weekly weigh-ins, maintaining consistent eating patterns across weekdays and weekends, and early intervention if weight increases by 2-3kg above goal weight. Your UK prescriber can provide referrals to registered dietitians or behavioural support programmes that complement pharmaceutical maintenance.

Managing Weight Fluctuations During Maintenance

Minor weight fluctuations of 1-2kg are normal during maintenance and don't necessarily indicate treatment failure. Hormonal cycles, sodium intake, exercise-induced inflammation, and bowel patterns all influence short-term weight changes. Establishing a maintenance range rather than a single target number (e.g., 70-72kg rather than exactly 71kg) provides psychological flexibility whilst maintaining accountability.

If weight increases beyond 3kg above your goal weight despite adherence to your maintenance dose and lifestyle plan, contact your prescriber promptly. Early intervention through temporary dose adjustment or intensified lifestyle support typically prevents substantial regain more effectively than waiting until significant weight has returned.

Cost Considerations for Long-Term Wegovy Maintenance UK

Long-term medication costs represent an important consideration when planning Wegovy maintenance. At Cured Pharmacy, transparent upfront pricing from £79.00 per month allows you to budget accurately for ongoing treatment, with prices displayed before your clinical consultation.

Some patients explore whether stepping down to lower maintenance doses might reduce costs whilst preserving results. Whilst lower doses are less expensive, the cost differential must be weighed against the risk of weight regain, which could necessitate restarting at higher doses or pursuing additional interventions. Your prescriber can discuss the cost-effectiveness of different maintenance strategies based on your individual response pattern.

Private prescription costs for weight management medications are not currently covered by most UK health insurance policies, though this landscape may evolve as long-term metabolic benefits become increasingly recognised. Setting up a dedicated savings allocation for ongoing treatment costs supports adherence and prevents financial barriers from interrupting successful maintenance.

When to Consider Stopping Wegovy After Goal Weight

Whilst most clinical evidence supports continued treatment for sustained weight maintenance, certain circumstances may warrant a trial discontinuation under close prescriber supervision. Patients who have maintained goal weight for 12+ months, implemented robust lifestyle changes, and demonstrate strong self-monitoring behaviours may be candidates for a supervised medication holiday.

A structured discontinuation approach involves gradually reducing the dose over 8-12 weeks rather than stopping abruptly, maintaining intensive lifestyle support and monitoring, and establishing clear criteria for restarting treatment if weight regain exceeds predetermined thresholds. This approach acknowledges that obesity is a chronic condition whilst respecting patient autonomy and preferences [2].

Pregnancy planning represents a clear indication for stopping Wegovy, as semaglutide is not recommended during pregnancy or breastfeeding. Women should discontinue treatment at least two months before attempting conception. Other medical circumstances requiring discontinuation include severe gastrointestinal side effects unresponsive to dose adjustment, diagnosis of medullary thyroid carcinoma or MEN 2 syndrome, or development of acute pancreatitis.

Switching to Alternative Maintenance Strategies

Some patients may consider switching from Wegovy to alternative weight maintenance approaches after achieving their goal. Options include transitioning to oral medications like orlistat or naltrexone-bupropion, though these typically provide less robust weight maintenance than continued GLP-1 therapy. Another emerging option involves switching to tirzepatide (Mounjaro), which demonstrated superior weight loss in head-to-head trials, though this approach is subject to clinical appropriateness and prescriber assessment [5].

Any treatment switch should occur under close prescriber supervision with careful monitoring during the transition period. Your UK clinical team at Cured Pharmacy can assess whether alternative maintenance strategies align with your goals, medical history, and long-term sustainability preferences.

Scientific References

1. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. Retrieved from https://products.mhra.gov.uk/ [accessed 13 August 2026]
4. Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or adjusting your current treatment plan.